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North Carolina
On October 29, 2004, the North Carolina Division of Public Health (NCDPH) received a report of a cluster of three HUS cases among children who visited a petting zoo at the North Carolina State Fair (Figure) . Approximately 800,000 visitors attended this fair during October 15-24, 2004. The fair had two petting zoos (petting zoos A and B).
NCDPH notified all local health departments to report cases of diarrheal illnesses. Intensified surveillance identified 108 persons who became ill, with onset after fair attendance and without other known cause. Eighty-two (78%) reported visiting a petting zoo at the state fair. Median age was 5 years (range: 1-61 years); 64 (59%) were female. Illness onsets were consistent with exposure during the fair dates. Fifty-two (48%) persons reported bloody diarrhea, and 48 (44%) reported fever. Forty-one cases were laboratory-confirmed Shiga toxinproducing E. coli (STEC) infections, of which 38 yielded E. coli O157:H7 isolates indistinguishable by pulsed-field gel * An acute condition characterized by microangiopathic hemolytic anemia, renal injury, and low platelet count.
FIGURE. A child stands near goats and goat droppings in a petting zoo at the 2004 North Carolina State Fair
Photo/North Carolina Division of Public Health electrophoresis (PFGE). Twenty patients (19%) were hospitalized, and 15 (14%) had HUS diagnosed. Systematic environmental sampling of the fairgrounds identified extensive E. coli O157:H7 contamination at one of two petting zoos (petting zoo B). Analysis of isolates from 30 systematically obtained environmental samples revealed a PFGE pattern indistinguishable from the predominant clinical isolate pattern. No other PFGE patterns from isolates at this site were noted after systematic sampling.
NCDPH, in collaboration with CDC, conducted a casecontrol study to identify risk factors for infection. Forty-five case-patients and 188 controls were enrolled; these were frequency-matched to cases in three age groups (0-5 years, 6-17 years, and >18 years). Confirmed cases in the study were those in persons who 1) had laboratory-confirmed E. coli O157:H7 infection or clinically diagnosed HUS with onset after October 15, 2004, 2) reported fair attendance, and 3) had illnesses that were not acquired from secondary transmission. Probable cases were those in persons who reported bloody diarrhea (three or more loose stools per 24-hour period) beginning after fair attendance without other known cause and were determined not to have acquired infections from secondary transmission. Controls attended the fair and reported no diarrheal illness through November 7, 2004 . Potential controls were identified from a randomized list of 23,972 persons who purchased tickets to the fair online, at kiosks, or in malls. The study questionnaire included items about human/animal interactions, food and beverage consumption, and hygiene practices. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were computed for various exposure variables.
No specific food, beverage, or recreational water exposure was associated with illness. Thirty-six (80%) of 45 casepatients visited petting zoo B, which was noted to have extensive environmental contamination, compared with 64 (34%) of 187 controls (AOR = 8.2; CI = 3.6-18.9). This petting zoo contained approximately 100 goats and sheep in an area where visitors could have extensive contact with animals and their bedding ( Figure) . Case-patients reported spending a median of 20 minutes in petting zoo B, compared with 15 minutes for controls (p = 0.04). Visits to petting zoo A were not associated with illness.
Among children aged <6 years who visited petting zoo B, illness was associated with touching or stepping in manure (OR = 6.9; CI = 2.2-21.9). Behaviors such as falling or sitting on the ground (OR = 3.2; CI = 1.1-9.1) and use of a pacifier or "sippy" cup or sucking on one's thumb while in petting zoo B (OR = 11.0; CI = 2.0-55) also were associated with illness. Reported alcohol-based hand sanitizer use was not protective (OR = 1.9; CI = 0.3-10.2). Reported awareness (among adults who accompanied children) of risk for disease from contact with livestock was protective (OR = 0.1; CI = 0.03-0.5).
Florida
In March 2005, Florida health officials identified a cluster of 22 E. coli O157:H7 infections, including seven HUS cases, related to attendance at Florida Fairs and Festivals during February 10-21, 2005 , and March 3-13, 2005. Early patient interviews identified no common food or water exposure but did implicate a common animal exposure (i.e., petting zoo attendance). Three implicated fairs had one common animal vendor, an exhibitor of a farm animal petting zoo. The petting zoo owner was contacted on March 24, and the animals (sheep, goats, and cattle) were placed under voluntary quarantine.
Stool samples from suspected cases were sent to the Florida Department of Health (FDOH) Bureau of Laboratories for culture and PFGE typing of E. coli O157:H7 isolates. Stool samples also were collected from 36 animals exhibited at two of three implicated petting zoos. Environmental samples were taken from exhibit grounds of implicated petting zoos from the three fairs. Twenty-four human stool samples, six animal stool samples, and 20 environmental samples yielded E. coli O157:H7 isolates with an identical PFGE pattern. The implicated farm animals were put under state quarantine by the Florida Department of Agriculture and Consumer Services on April 8.
FDOH intensified surveillance by requesting rapid reporting of suspected E. coli O157:H7 infections and HUS cases. Sixty-three patients were identified who had symptoms of E. coli O157:H7 infection within 10 days or HUS within 21 days after visiting the implicated fairs and who had no alternate diagnosis to explain their symptoms; of these, 20 (32%) persons had culture-confirmed E. coli O157:H7 infection. Four persons had culture-confirmed infection; however, these cases did not meet the case definition.
Median patient age was 4 years (range: 1-63 years); 35 (56%) patients were female. Clinical features included diarrhea in 63 (100%) patients, vomiting in 28 (44%), abdominal cramps in 27 (43%), and fever in 23 (37%). Seventeen patients (27%) were hospitalized, and seven (11%) had diagnoses of HUS (three of the seven patients with HUS did not have E. coli O157:H7-positive stool cultures).
Thirty-four ill persons (54%) were reported to have touched at least one cow, sheep, or goat. Twenty (32%) reportedly fed at least one cow, sheep, or goat. Preliminary analysis of a casecontrol study that included 34 case-patients and 176 controls (identified from credit card receipts from the fairs and defined as persons who went to the petting zoo and remained well) found a positive association between illness and both direct animal contact (e.g., 71% of case-patients and 47% of controls touched a cow [OR = 4.2; CI = 1.7-10.5]) and indirect (e.g., 33% of case-patients and 12% of controls touched sawdust or shavings [OR = 3.3; CI = 1.4-7.8]) animal contact.
Arizona
In July 2005, two children hospitalized with E. coli O157:H7 infection were reported to the Arizona Department of Health Services. Isolates from the two children had indistinguishable PFGE patterns. Both children had visited a zoo in Arizona that contained a petting zoo. No common food or beverage was consumed by the two children at the zoo, and the children were not related. One child had direct contact with petting zoo animals; the second child only had possible contact with exterior railings at the petting zoo. Both children had played in an area immediately adjacent to and downhill from the petting zoo facility. Fifteen of 25 (60%) fecal specimens from petting zoo animals yielded E. coli O157:H7; 12 isolates had PFGE patterns indistinguishable from the clinical isolates. Upon notification of the results, zoo officials immediately closed the petting zoo and adjacent play area.
Editorial Note: E. coli O157:H7 causes approximately 73,000 illnesses in the United States annually, leading to an estimated 2,168 hospitalizations and 61 deaths (1) . HUS is a principal cause of acute renal failure among children in the United States and occurs in 3%-7% of E. coli O157:H7 infections (2). Among patients with HUS, approximately 3%-5% die as a result (2) . Most cases of diarrhea-associated HUS are caused by STEC, of which E. coli O157:H7 has the strongest association with HUS worldwide (3). At least 80% of childhood HUS is attributable to infection with STEC, primarily E. coli O157:H7 (4).
The primary animal reservoir for E. coli O157:H7 is ruminant livestock, which are asymptomatically colonized. The primary route of transmission for E. coli O157:H7 is foodborne; however, among 350 E. coli O157:H7 outbreaks reported in the United States during 1982-2002, the transmission route for 11 (3%), accounting for 319 cases, was animal contact (5 described in this report, accounting for 173 cases and associated with direct and indirect animal contact at petting zoos, emphasize the need for adequate control measures to reduce zoonotic transmission. In the North Carolina outbreak, extensive direct animal contact occurred in an area contaminated with manure. In the Florida outbreak, illness was associated with touching and feeding animals and indirect animal contact (e.g., touching sawdust or shavings or visibly soiled clothes or shoes). In the Arizona outbreak, at least one case likely resulted from exposure in the play area adjacent to the petting zoo, where contamination via drainage from the petting zoo was suspected. In certain instances, exposure to E. coli O157:H7 might have occurred before petting zoo patrons could practice hand hygiene. Also, exposure from contaminated clothes, shoes, strollers, or other fomites might have occurred before or after hand-hygiene practice.
Experience from these and previous outbreaks (6,7) underscores the necessity of using sensitive laboratory isolation methods, such as those used in these outbreaks, for detecting E. coli O157:H7 from livestock feces and agricultural environmental samples. Had direct plating methods used for human stool been the only method used to recover E. coli O157:H7 from environmental samples, many positive specimens would have been undetected. Because of the multiple, competing microorganisms in livestock fecal material and soil, selective culture conditions, including selective broth enrichment, immunomagnetic separation, and plating on selective media, should be used (6) .
In 2001, CDC issued guidelines to reduce the risk for transmission of enteric pathogens at venues where the public has contact with animals (8) . In March 2005, the National Association of State Public Health Veterinarians (NASPHV) published recommendations on hand washing, venue design, animal care and management, and risk communication regarding disease transmission for staff and visitors (9) .
Petting zoos are minimally regulated. Guidelines based on the NASPHV compendium were adopted by the North Carolina Department of Agriculture and Consumer Services (NCDACS) after the outbreak. In addition, a law † was enacted in North Carolina in July 2005 that requires sanctioned agricultural fairs to obtain a permit from NCDACS for all animal exhibitions open to the public. The Arizona Department of Health Services adapted the NASPHV compendium recommendations into educational packets distributed to petting zoo operators statewide.
These recent petting zoo-associated E. coli O157:H7 outbreaks highlight the need to strengthen control measures for such exhibits to reduce disease transmission and prevent similar outbreaks. To reduce human exposure to manure, revised control measures should be considered, particularly those restricting young children from directly entering open-interaction areas of petting zoos.
(LTBI) after testing positive 11 years earlier. An investigation including medical evaluation of contacts in the nursery and maternity ward was conducted by the Bureau of TB Control (BTBC) at the New York City Department of Health and Mental Hygiene, hospital A, and CDC. This report summarizes the results of that investigation, which determined that approximately 1,500 patients had been exposed to the nurse but the majority could not be located for evaluation. Among those who were tested, four infants had positive tuberculin skin test (TST) results, likely attributable to recent transmission of M. tuberculosis. The findings emphasize the difficulty of conducting contact investigations in certain settings and the importance of effective LTBI testing and treatment programs for health-care workers (HCWs) to prevent TB disease and subsequent health-care-associated transmission.
In December 2003, a female nurse (nurse A) working in the newborn nursery and maternity ward at hospital A received a diagnosis of acid-fast bacilli (AFB) sputum smearpositive, noncavitary pulmonary TB disease. Eleven years earlier, nurse A had LTBI diagnosed with a TST result of 15 mm induration during screening for employment at hospital A, after emigrating from the Philippines. She had elected not to take the isoniazid prescribed for treatment. The reason nurse A gave for declining treatment was that most adults from the Philippines, where TB is endemic, have positive TST results and generally do not take treatment for LTBI. She also stated that the positive TST result might have been caused by her bacille Calmette-Guérin (BCG) vaccination for TB disease at birth or potential exposures while she was employed as a nurse in the Philippines. Nurse A had an annual TB symptom screen on eight other occasions and had one other chest radiograph (when she began work in a different area of the hospital) without evidence of TB disease. Nurse A's symptoms began in September 2003 as a productive cough, wheezing, and shortness of breath. Her initial chest radiograph was interpreted as "normal heart and lungs" by a radiologist at hospital A. She was symptomatically treated for asthma with inhaled beta-agonists, inhaled steroids, oral steroids, antihistamines, and a cough suppressant. After her symptoms persisted for approximately 8 weeks, she underwent a chest computed tomography scan (CT) and, approximately 1 week later, bronchoscopy. The CT revealed bilateral upperlobe disease with volume loss and calcified mediastinal lymph nodes. The leading diagnosis at the time was hypersensitivity pneumonitis. Specimens from a transbronchial biopsy, routinely sent for microscopic examination, revealed rare AFB; culture of bronchial alveolar lavage subsequently yielded M. tuberculosis that was susceptible to the four first-line anti-TB drugs. Genotyping of the M. tuberculosis isolate did not match any pattern in the New York City or national databases.
Nurse A subsequently was screened for human immunodeficiency virus (HIV) and had a negative HIV test result.
On the basis of nurse A's AFB smear status at start of treatment, her infectious period was defined as September 1-November 29, 2003. Work schedules and hospital records for all coworkers and patients in the newborn nursery and maternity ward who were contacts of nurse A during this period were reviewed to identify and prioritize contacts and to assess risk factors for transmission. During her infectious period, nurse A worked 60 night shifts at hospital A and potentially exposed 32 coworkers, 613 infants in the newborn nursery, and 900 patients in the maternity ward. During a 7-month period, hospital A and BTBC took the following measures to notify contacts: 1) mailing certified letters, making telephone calls, and attempting home visits to hospital patients and to mothers and guardians of all infants; 2) faxing notifications to all pediatric providers in the area; and 3) crossmatching the list of exposed infants with names in the city's immunization registry. All contacts were offered a free medical evaluation, including a TST; if indicated, contacts also were offered chest radiography and sputum specimen collection to exclude a diagnosis of TB disease. Results were reviewed to estimate the extent of transmission.
Of the 32 potentially exposed coworkers, 25 (78%) had a previously documented positive TST baseline result, and none had taken treatment for LTBI. On screening, none of these 25 persons had symptoms for TB; they were offered LTBI treatment, but all 25 declined. TSTs were administered to the remaining seven coworkers, all with negative results.
The majority of patients in the maternity ward had received TSTs and HIV screening during the prenatal period. Extensive outreach by the hospital and city health department workers resulted in medical evaluation of 227 (37%) of the 613 infant contacts and 216 (24%) of the 900 female contacts. None of these contacts were determined to have TB disease. TST results were positive (>5 mm) for five (2%) of 227 infants, including one who had received BCG vaccination during a family trip to the Dominican Republic. A positive TST result among infants was determined to be associated with cesarean delivery (relative risk [RR] = 11.8, 95% confidence interval [CI] = 1.3-103.1). TST results of 19 (9%) of 216 women with a prior negative test changed to positive (>5 mm). Change in TST result was associated with foreign birth among women (RR = 5.9, CI = 1.4-24.5). No association was evident between a positive TST result or change in TST result and duration of contact (e.g., estimated time in the hospital while nurse A was working) or type of contact (e.g., receiving direct care) with nurse A.
Of the 900 patients admitted to the maternity ward during nurse A's infectious period, 807 were admitted for postpartum care and 93 for gynecologic indications or complications during pregnancy. Documentation of HIV test results were available for 806 of the 807 postpartum patients; 16 (2%) tested positive for HIV infection. Of these HIV-infected females, 13 delivered infants admitted to the newborn nursery (12 single infants and one twin birth). These 16 women and 14 infants were assigned the highest priority for follow-up testing. Three of the women and seven of the infants were located and tested for TB; none had evidence of LTBI or TB disease.
BTBC recommended LTBI treatment with isoniazid daily for 9 months for all contacts with a positive TST result, after TB disease was excluded. BTBC also recommended LTBI treatment for all HIV-infected persons exposed to nurse A and infants whose mothers had known HIV infection, regardless of their TST results, after TB disease was excluded (2). Editorial Note: The findings in this report underscore the difficulty and substantial resources required to conduct contact investigations and provide appropriate follow-up for patients exposed to M. tuberculosis in health-care settings. Despite extensive outreach efforts, approximately 70% of nurse A's patient contacts could not be traced. Hospital A was located in an economically depressed community. Hospital records of telephone numbers and addresses for many of the patients were incorrect. Nonetheless, evidence indicated that limited transmission of M. tuberculosis had occurred in hospital A. The strongest evidence of transmission was that four infants had positive TST results (a fifth infant tested positive but had recently received BCG vaccination), which in children is a sentinel indicator for recent transmission of M. tuberculosis.
In this investigation, the only risk factor significantly associated with M. tuberculosis transmission to the infants was cesarean delivery. Post-cesarean infants might have required more nursing care, thus resulting in more exposure. A major limitation of this investigation was the incomplete follow-up of all exposed patients. In addition, the extent of M. tuberculosis transmission to the most heavily exposed group, nurse A's coworkers, was difficult to ascertain because 78% had positive TST baseline results.
Nurse A underwent bronchoscopy before TB disease was clinically suspected. Because bronchoscopy is a coughinducing procedure that can result in increased transmission of M. tuberculosis, diagnosis of TB disease and microscopic examination of sputum for AFB should be considered before bronchoscopy (3) . CDC recommends avoiding bronchoscopy if possible for patients with suspected or confirmed TB disease or postponing the procedure until the patient is determined to be noninfectious by confirmation of three negative AFB sputum smear results. If the patient cannot produce sputum, CDC recommends considering sputum induction before bronchoscopy (3) .
Eleven years after her LTBI was detected, nurse A had infectious pulmonary TB disease diagnosed. An opportunity to prevent TB disease was missed when she did not complete treatment for LTBI. In light of the investigation described in this report, hospital A began exploring ways to promote LTBI treatment for employees with positive TST results during annual screenings for TB. Although the nurse did not have HIV infection, it is the greatest risk factor for progression from LTBI to TB disease (2) . Therefore, voluntary HIV counseling, testing, and referral should be routinely offered to all persons at risk for LTBI. Health-care settings should be particularly aware of the need to prevent transmission of M. tuberculosis in settings where persons infected with HIV might be encountered or might work.
In 2002, the incidence of TB disease among foreign-born HCWs in the state of New York was 17.5 per 100,000, compared with 2.0 among U.S.-born HCWs (4). During 1998-2002, among 297 HCWs (employed in hospitals, home health care, nursing homes, and ambulatory care facilities) who were reported to have TB disease, 221 (74%) had had LTBI diagnosed previously. Of these, 111 (50%) had met criteria for treatment for LTBI, but only 26 (23%) of these received treatment (4) . Those data and the circumstances described in this report support the need for effective LTBI testing and treatment programs among HCWs, particularly those born outside the United States.
Studies have demonstrated poor adherence to LTBI treatment among HCWs (5). HCWs might attribute a positive TST result to BCG vaccination (6) . Compared with U.S.-born physicians, foreign-born physicians in one U.S. medical residency program were less likely to recommend LTBI treatment for themselves, their family members, or recent immigrants if they had received BCG vaccination (7) . However, in the absence of M. tuberculosis infection, tuberculin reactivity caused by BCG vaccination wanes over time and is unlikely to persist >10 years after vaccination (8) . Current guidelines recommend considering treatment for HCWs who have a TST result of >10 mm, especially if they emigrated from a country with high TB prevalence during the preceding 5 years (3). A history of vaccination with BCG should not influence the decision to treat LTBI.
The proportion of HCWs in the United States who were born outside the country is growing (9, 10) . Approximately 25% of all U.S. practicing physicians graduated from medical schools outside of the United States (9) . Moreover, the shortage of registered nurses in the United States is anticipated to increase from 6% in 2000 to 29% by 2020, and foreign-born nurses likely will increasingly be sought to fill this gap (10) . All HCWs in the United States, particularly those foreignborn or foreign-trained, should be encouraged to follow U.S. guidelines for LTBI treatment. Guidelines for preventing transmission of M. tuberculosis in health-care settings, including baseline and periodic TB screening and effective LTBI treatment programs for HCWs in high-risk settings, should be followed (3) . In addition, infection-control programs in healthcare settings should implement interventions to increase adherence to treatment for infected HCWs working in highrisk settings. On-site, directly observed preventive therapy is one such option.
Pertussis is a highly contagious, vaccine-preventable bacterial illness characterized by paroxysmal cough, posttussive vomiting, and inspiratory whoop. Pertussis also can occur as a mild or moderate cough illness in persons who are partially immune (1) . In the United States, most hospitalizations and nearly all deaths from pertussis are reported in infants aged <6 months, but substantial morbidity does occur in other age groups. Infant/childhood vaccination has contributed to a reduction of more than 90% in pertussis-related morbidity and mortality since the early 1940s in the United States (1). Estimates of childhood vaccination coverage with >3 doses of pertussis-containing vaccine have exceeded 90% since 1994; however, reported pertussis cases increased from a historic low of 1,010 in 1976 to 11,647 cases in 2003 (2) . A substantial increase in reported cases has occurred among adolescents, who become susceptible to pertussis approximately 6-10 years after childhood vaccination (3, 4) . Recently, booster vaccines for adolescents and adults combining pertussis antigens with tetanus and diphtheria toxoids (Tdap) were approved by the Pertussis cases are reported weekly by state health departments to CDC through the National Notifiable Diseases Surveillance System (NNDSS); more detailed information about cases is provided through the linked Supplementary Pertussis Surveillance System (SPSS). Probable and confirmed cases are reported; however, six states do not report probable cases. A clinical case is defined as an acute cough illness lasting >14 days in a person with at least one symptom characteristic of pertussis (i.e., paroxysmal cough, posttussive vomiting, or inspiratory whoop) or >14 days of cough in an outbreak setting. A confirmed case is defined as 1) a cough illness of any duration with isolation by culture of Bordetella pertussis or 2) a case that is consistent with the clinical case definition and is confirmed by polymerase chain reaction (PCR) testing or epidemiologic linkage to a laboratory-confirmed case. In addition, Massachusetts uses an in-state, standardized serologic assay for persons aged >11 years as a confirmatory test. A probable 6 ,608 (23%) were aged <1 year (including 5,872 aged <6 months), 3,353 (12%) were aged 1-4 years, 2,553 (9%) were aged 5-9 years, 9,609 (33%) were aged 10-19 years, and 6,800 (23%) were aged >20 years ( Figure 1) . By age group, average annual incidence was highest (55.2 per 100,000 population) among infants aged <1 year; within that group, incidence was 98.2 for infants aged <6 months and 12.3 for infants aged 6-11 months. Incidence was lower for older groups: 7.2 per 100,000 population for children aged 1-4 years, 4.3 for children aged 5-9 years, 7. Race and Hispanic ethnicity were considered independently. Data on race were available for 24,024 (83%) persons with pertussis. Of these, 21,597 (90%) were white, 1,621 (7%) were black, 288 (1%) were American Indian/Alaska Native, 337 (1%) were Asian/Pacific Islander, and 181 (1%) were identified as "other race." Among the 7,991 (83%) persons aged 10-19 years whose race was reported, 7,549 (95%) were white and 265 (3%) were black. Among all age groups, the incidence of reported cases was twice as high among whites as among blacks (3.0 versus 1.4 cases per 100,000 population). After stratifying by state, the white-to-black incidence rate ratio was 1.6. Data on Hispanic ethnicity were available for 23,669 (82%) persons with pertussis. Of these, 3,871 (16%) were Hispanic. Among infants aged <6 months, 1,701 (29%) of 5,872 with pertussis were Hispanic; by comparison, an estimated 18% of infants born each year in the United States are Hispanic.
Of 9,609 persons aged 10-19 years with reported pertussis, 116 (1%) of 8,286 for whom information was provided were hospitalized, 148 (2%) of 7,560 had radiographically confirmed pneumonia, and 20 (0.2%) of 8,543 reported seizures as a complication of pertussis. Hospitalization and complications of pertussis were most common among infants aged <6 months. Of the total 5,872 infants aged <6 months, 3,255 (69%) of 4,748 for whom information was provided were hospitalized, 532 (13%) of 4,096 had radiographically confirmed pneumonia, and 79 (2%) of 4,802 had seizures. Among persons of all ages with pertussis, 33 cases of encephalopathy and 56 pertussis-related deaths were reported during 2001-2003. Fifty-one (91%) of the deaths were among infants aged <6 months, and 42 (75%) of the deaths were among infants aged <2 months.
Compared with other age groups, the greatest number of reported cases was among persons aged 10-19 years. Among the 6,090 (63%) of 9,609 persons in this age group reported as having confirmed pertussis, 1,570 cases (26%) were confirmed by an epidemiologic link to a confirmed case, 1,356 (22%) by culture, 1,562 (26%) by PCR, and 1,511 (25%) by the Massachusetts serologic test (Figure 2 ). Massachusetts alone reported 1,812 cases, accounting for 19% of the total U.S. cases in persons aged 10-19 years; by comparison, Massachusetts has 2% of the U.S. population aged 10-19 years. Massachusetts had the highest state average annual incidence in this age group (78.8 per 100,000 population); the median state average annual incidence for this age group was 3.7 per 100,000 population (range: 0-78.8) (Figure 3 ). in cases reported in age groups that contain recently vaccinated children have been small (5, 6) . Compared with older age groups, infants aged <6 months continued to have the highest reported incidence of pertussis, and Hispanic infants were overrepresented in this group, as also demonstrated in a previous study (7) . Among all age groups, the reported pertussis incidence in whites was higher than the incidence in blacks. However, passive surveillance probably does not equally reflect the relative burden of pertussis in all racial and ethnic groups; even among reported cases, race and ethnicity data were complete in only 74% of cases.
How much the increase in reported cases of pertussis in adolescents reflects a true change in the burden of disease remains unclear. Better recognition, diagnosis, and reporting of pertussis in persons aged 10-19 years likely has contributed to the greater number of cases reported. Although the Council of State and Territorial Epidemiologists has made no changes to the case definition for pertussis since 1996 (when PCR was added as a confirmatory test for cases that also are consistent with the clinical case definition), an increasing number of states now use PCR for confirmatory testing. In addition, heightened recognition of pertussis transmitted in schools and other settings likely adds to the number of cases detected and reported among persons aged 10-19 years. Wide variability was observed in incidence of cases reported by individual states. Massachusetts, for example, has long reported higher incidence in adolescents compared with other states, and Massachusetts data are believed to more closely reflect the pertussis burden in U.S. adolescents (8) . These results from Massachusetts have been obtained, in part, through the state's enhanced pertussis surveillance among students in middle and high school and through development and availability of a serologic test for pertussis in persons aged >11 years. Awareness of pertussis in adolescents, however, is still low in many places, as suggested in part by eight states reporting an average annual incidence of <1 case per 100,000 persons aged 10-19 years during the 3-year period. A population-based, active surveillance study during 1995-1996 estimated pertussis incidence at 507 per 100,000 population aged 10-49 years, demonstrating that passive pertussis surveillance is capturing only a fraction of cases among older persons (9) .
Diagnostic testing for pertussis remains inadequate for surveillance and clinical management. Culture is specific but not sensitive. PCR is likely more sensitive, but no FDA-licensed test kit is available and no nationally accepted standardized protocol for test performance exists. Most laboratory validation studies have not sufficiently established the predictive value of a positive PCR test in cases of pertussis; the rate of false-positive tests varies from laboratory to laboratory (10) . PCR-confirmed cases contribute a substantial proportion of the total reported cases among persons aged 10-19 years. Moreover, many cases confirmed by epidemiologic linkage to laboratory-confirmed cases are linked to PCR-confirmed cases, potentially multiplying the contribution of PCR testing to the overall number of cases reported. Cases that are PCR The source of contamination and the extent to which biofilm growth might be a contributing factor remain unknown. Although the majority of organisms found in Vapotherm devices by CDC and reporting institutions have been Ralstonia spp., other bacteria (e.g., Burkholderia cepacia, Alcaligenes xylosoxidans, Klebsiella pneumoniae, Proteus mirabilis, and Sphingomonas paucimobilis) have been recovered from used cartridges or machines. CDC continues to work with the manufacturer and FDA to determine the source of contamination of Vapotherm devices.
Ralstonia spp. are gram-negative bacteria found in the environment, primarily in water, soil, and on plants; occasionally Ralstonia spp. are isolated from clinical samples (e.g., respiratory secretions of cystic fibrosis patients). These organisms formerly were included in the genus Pseudomonas or Burkholderia; however, DNA characterization has revealed Ralstonia to be a distinct genus. The organism grows readily on media routinely used by clinical microbiology laboratories (i.e., trypticase soy agar with 5% sheep blood or MacConkey agar) (3). When both biochemical tests and automated identification systems are used, Ralstonia spp. can be misidentified as Burkholderia spp. or, less often, as non-aeruginosa Pseudomo-nas spp. Signs and symptoms of an infection with Ralstonia are similar to those observed in other bacterial infections. Infections caused by Ralstonia spp. should be treated on the basis of results of susceptibility testing of the patient's isolate.
The current labeling for the Vapotherm device was cleared for marketing on August 18, 2004, with the indication, "to add moisture to and to warm breathing gases for administration to patients." Other devices are marketed for this general indication. FDA and CDC currently recommend use of alternative devices until the source of contamination can be identified. A list of humidifiers can be found in the FDA 510(k) database, by entering "BTT" in the "Product Code" field. † Several heated humidifiers on the list have specifications similar to the Vapotherm device. Humidifiers will require a gas source, connectors, and a patient interface (mask or nasal cannula) to make a complete system for administration of breathing gas.
Clinicians who elect to use Vapotherm are encouraged to weigh the risk of potential bacterial contamination of the device against the benefits Vapotherm might provide patients who require humidified oxygen therapy. Patients who have been exposed to Vapotherm should be monitored for signs and symptoms of infection, and clinicians should consider Ralstonia spp. infection in the differential diagnosis of exposed, symptomatic patients.
Hospitals should report cases of colonization or infection with Ralstonia or related bacteria (gram-negative rods) in patients exposed to Vapotherm directly to the device manufacturer and local or state public health departments and CDC by telephone 800-893-0485. Adverse events associated with medical devices should be reported to MedWatch, FDA's voluntary reporting program at http://www.fda.gov/Medwatch/ report.htm; by telephone, 800-FDA-1088; by fax, 800-FDA-0178; or by mail, MedWatch, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20852-9787.
Supplemental Testing for Confirmation of Reactive Oral Fluid Rapid HIV Antibody Tests
On December 16, this report was posted as an MMWR Dispatch on the MMWR website (http://www.cdc.gov/mmwr).
In A reactive rapid HIV test result is considered preliminary and must be confirmed by supplemental testing (1). Some false positive rapid test results (i.e., reactive rapid test results followed by negative supplemental test results) are to be expected within the range of specificity for the device. However, in late 2005, HIV testing programs in multiple U.S. cities experienced apparent clusters of false-positive rapid HIV test results using oral fluid (but not whole blood) specimens. Counselors at these programs have expressed concern regarding the specificity and positive predictive value of the oral fluid rapid HIV test. The published sensitivity and specificity for the test using oral fluid are 99.3% (95% confidence interval [CI] = 98.4%-99.7%) and 99.8% (CI = 99.6%-99.9%), respectively. CDC has received multiple inquiries concerning whether its guidelines for confirmatory testing for reactive rapid HIV tests on oral fluid specimens have been modified.
CDC is actively working with FDA, state and local health officials, and the product manufacturer to investigate these reports, assess the test's current performance, and consider whether changes in testing protocols should be recommended or any other actions taken. In the meantime, current protocols for confirmation of reactive rapid HIV test results should continue to be followed (2) . These protocols ensure that clients with reactive rapid test results receive accurate HIV test results after confirmation. HIV counselors returning reactive (preliminary positive) results from HIV rapid tests to clients should provide the same counseling message that is currently recommended (3), regardless of whether the reactive test result was obtained using oral fluid or whole blood. HIV testing program directors who have noted any problems or who have concerns over the performance of the OraQuick Advance Rapid HIV-1/2 Antibody Test in their particular settings should report these concerns to OraSure Technologies at telephone 800-672-7873. 
